After a biosimilar or interchangeable product gets regulatory approval by the USFDA, manufacturers often need to adjust their manufacturing processes. These changes after approval are essential for keeping product consistency, enhancing processes, or tackling operational issues. However, because biologics are complex, even small modifications can significantly affect the product’s safety, efficacy, and quality. As a result, a strong regulatory framework oversees these changes to ensure that the product’s integrity and patient safety are upheld.
The U.S. Food and Drug Administration (FDA) has issued detailed guidelines to ensure that these changes are appropriately regulated, focusing on evaluating their impact on product quality.
Regulatory Framework for Manufacturing Changes
Under section 351(k) of the Public Health Service (PHS) Act, biosimilar and interchangeable products can obtain approval through a streamlined process by proving they are highly similar to their reference biologics, with no significant differences in safety, purity, and potency. However, like their reference products, biosimilars may need manufacturing changes after approval. Any changes related to the production process, equipment, or facilities must be reported and assessed to ensure they do not negatively impact the product’s quality.
The FDA’s guidance on post-approval manufacturing changes categorizes the changes into three reporting categories, each requiring different levels of documentation and regulatory oversight-
- Prior Approval Supplement (PAS): Major changes with the potential to significantly affect product quality require a PAS. These changes must receive FDA approval before the modified product is distributed. This includes changes that could alter the identity, strength, quality, purity, or potency of the product.
- Changes Being Effected (CBE): Moderate changes that may have a moderate potential to impact product quality can be submitted as CBE-30 supplements, meaning the changes can be implemented 30 days after submission unless otherwise instructed by the FDA. If the risk is lower, a CBE-0 allows the product to be distributed immediately upon submission.
- Annual Report: Minor changes with minimal risk to product quality, such as adjustments in documentation, are reported annually.
Considerations for Post-Approval Manufacturing Changes
Post-approval manufacturing changes in biosimilars must be rigorously assessed to ensure that they do not affect the biosimilar’s or interchangeable product’s ability to maintain the same clinical performance as its reference product. The following aspects are particularly important-
- Comparability Exercises: When manufacturing changes occur, manufacturers must demonstrate that the pre-change and post-change products are comparable. The FDA advises using a risk-based approach, focusing on critical quality attributes that could be impacted by the change. Data such as stability testing, and process validation should be included in submissions to ensure the product remains safe and effective post-change.
- Analytical Testing and Validation: Detailed analytical testing is crucial to confirm that changes in the manufacturing process do not result in clinically meaningful differences in the product. The FDA recommends including enough pre- and post-change lots in comparative studies to provide a robust evaluation.
- Control of Risks in Multiproduct Facilities: For manufacturers introducing biosimilars into facilities where other products, including reference biologics, are produced, preventing cross-contamination and ensuring product purity is paramount. The implementation of strong manufacturing controls, including separate areas or thorough cleaning processes, is essential.
Implications for Interchangeable Products
For interchangeable biosimilars, the stakes are higher because these products can be substituted for the reference biologic without the involvement of the prescriber. As a result, demonstrating comparability in the face of manufacturing changes is even more critical. Manufacturers must ensure that alternating or switching between the interchangeable product and its reference biologics does not present additional risks to patients.
Here’s a strategic approach to integrating the FDA’s guidance into your post-approval change processes:
- Understand Reporting Categories: Be familiar with the FDA’s categories of manufacturing changes, which range from major changes (requiring PAS submission) to minor ones (reported in the Annual Report). Assess the potential impact of any manufacturing change on product quality, safety, and efficacy.
- Submit the Correct Documentation: Prepare and submit the required documentation based on the type of change. A PAS should be submitted for major changes, a CBE-30 for moderate changes, and minor changes should be reported in the Annual Report.
- Conduct Thorough Comparability Studies: Ensure that biosimilar comparability exercises are comprehensive, covering quality attributes and supported by sufficient data to demonstrate that the product remains consistent pre- and post-change.
Conclusion
The FDA guidance on post-approval manufacturing changes for biosimilars and interchangeable products highlights the complexity and precision required in biologic manufacturing. It is essential to ensure that any changes in the production process do not affect the safety or efficacy of the product, as this is crucial for maintaining public trust in these vital therapies. By following the FDA’s reporting requirements and performing comprehensive comparability studies, manufacturers can consistently provide high-quality biosimilars and interchangeable products, which ultimately enhances patient access to important biologic treatments.
Reach out to DDReg for end-to-end regulatory services for cell and gene therapy products. With over 15 years’ experience of navigating regulations for over 120 regulatory agencies and in-depth subject matter expertise, DDReg is your go-to-partner for rapid market access. Read more from experts here- Recommendations for the use of Animal & Human Derived Materials in Cell and Gene Therapy Products